Showing results (161-170 of 232) with videos related to
Sort By:
Pageof 24
Clinical Pharmacology in Drug Development|April 29, 2016
Effect of Food, Antacid, and Age on the Pharmacokinetics of the Oral Thrombin Receptor Antagonist Vorapaxar (SCH 530348) in Healthy VolunteersTeddy Kosoglou, Larisa Reyderman, Jack Tseng, et al.New Directions for Mental Health Services|January 1, 1989
The evolution of Oregon's Public Psychiatry Training ProgramJ D Bloom, D L Cutler, L R Faulkner, et al.Clinical Pharmacology in Drug Development|April 30, 2016
Vorapaxar, an oral PAR-1 receptor antagonist, does not affect the pharmacokinetics of rosiglitazoneTeddy Kosoglou, Bharath Kumar, Paul Statkevich, et al.Journal of Clinical Pharmacology|February 22, 2013
The effect of multiple doses of ketoconazole or rifampin on the single- and multiple-dose pharmacokinetics of vorapaxarTeddy Kosoglou, Paul Statkevich, Bharath Kumar, et al.Journal of Clinical Pharmacology|October 12, 1999
Disposition of recombinant human interleukin-10 in subjects with various degrees of renal functionS R Andersen, L J Lambrecht, S K Swan, et al.Arthritis and Rheumatism|July 24, 2001
Stratification of flare intensity identifies placebo responders in a treatment efficacy trial of patients with osteoarthritisJ A Scott-Lennox, C McLaughlin-Miley, R D Lennox, et al.Clinical Therapeutics|September 19, 2018
Pharmacokinetics of Single-dose Ertugliflozin in Patients With Hepatic ImpairmentVaishali Sahasrabudhe, Steven G Terra, Anne Hickman, et al.European Journal of Clinical Pharmacology|September 22, 2011
Pharmacodynamics and pharmacokinetics of the novel PAR-1 antagonist vorapaxar (formerly SCH 530348) in healthy subjectsTeddy Kosoglou, Larisa Reyderman, Renger G Tiessen, et al.Chest|October 1, 2013
Hypothalamic-pituitary-adrenal axis effects of mometasone furoate/formoterol fumarate vs fluticasone propionate/salmeterol administered through metered-dose inhalerTeddy Kosoglou, James Hubbell, David L Cutler, et al.Clinical Therapeutics|September 2, 2018
Effect of Rifampin on the Pharmacokinetics of Ertugliflozin in Healthy SubjectsVikas K Dawra, Vaishali Sahasrabudhe, Yali Liang, et al.Pageof 24